Hoyer Dieter P, Mathé Zoltan, Gallinat Anja, Canbay Ali C, Treckmann Juergen W, Rauen Ursula, Paul Andreas, Minor Thomas
1 General, Visceral and Transplantation Surgery, University Hospital Essen, Essen, Germany. 2 Clinic for Gastroenterology and Hepatology, University Hospital Essen, Essen, Germany. 3 Institute of Physiological Chemistry, University Hospital Essen, Essen, Germany. 4 Surgical Research Division, University Hospital Bonn, Bonn, Germany.
Transplantation. 2016 Jan;100(1):147-52. doi: 10.1097/TP.0000000000000915.
Abrupt temperature shift from hypothermia to normothermia incurred on reperfusion of organ grafts has been delineated as a genuine factor contributing to reperfusion injury and graft dysfunction after transplantation.
In a first clinical series of 6 patients, cold-stored livers, all allocated by the rescue offer mechanism by Eurotransplant, were subjected to machine-assisted slow controlled oxygenated rewarming (COR) for 90 minutes before engrafting. A historical cohort of 106 patients basically similar in graft (all rescue offer organs) and recipient factors was used for comparison.
The clinical benefit of COR was documented by a significant reduction by approximately 50% in peak serum transaminases after transplantation compared to untreated controls (AST 563.5 vs. 1204 U/L, P = 0.023). After 6 months graft survival was 100% in the COR group and 80.9% in the controls (P = 0.24). Respective patient survival was 100% and 84.7% (P = 0.28). Real-time assessment of glucose concentration in the perfusion solution correlated well with postoperative synthetic graft function (r = 0.78; P < 0.02). All treated recipients had normal liver function after a 6-month follow-up and are well and alive.
This first clinical application suggests that controlled graft rewarming after cold storage is a feasible and safe method in clinical praxis and might become an adjunct in organ preservation.
器官移植再灌注时,移植器官从低温突然转变为正常体温已被确认为是导致移植后再灌注损伤和移植物功能障碍的一个真正因素。
在首个包含6例患者的临床系列研究中,所有通过欧洲移植组织的救援供体机制分配的冷保存肝脏,在植入前接受了90分钟的机器辅助缓慢控制性氧合复温(COR)。以一个历史队列中的106例患者作为对照,这些患者在移植物(均为救援供体器官)和受体因素方面基本相似。
与未治疗的对照组相比,COR的临床益处表现为移植后血清转氨酶峰值显著降低约50%(AST:563.5 vs. 1204 U/L,P = 0.023)。6个月后,COR组的移植物存活率为100%,对照组为80.9%(P = 0.24)。患者存活率分别为100%和84.7%(P = 0.28)。灌注液中葡萄糖浓度的实时评估与术后移植物合成功能密切相关(r = 0.78;P < 0.02)。所有接受治疗的受体在6个月随访后肝功能均正常,且健康存活。
这一首次临床应用表明,冷保存后控制性移植物复温在临床实践中是一种可行且安全的方法,可能成为器官保存的一种辅助手段。